All News

Your daily dose of the clinical news you may have missed.

The first FDA-approved oral GLP-1 receptor agonist received an expanded indication for both primary and secondary prevention in T2D patients at elevated CV risk.

Tezepelumab's approval marks the first for a TSLP-targeting biologic for CRSwNP, backed by WAYPOINT trial data showing sustained symptom and polyp reduction.

GRAIL's PATHFINDER 2 study shows Galleri blood test detected 7 times more cancers when added to standard screenings, with 99.6% specificity and low false positives.

Your daily dose of the clinical news you may have missed.

Vaccine-preventable diseases claim up to 50,000 adult lives each year in the US. Click through this compact reminder of recommended catch up shots for your patient panel.

Undertreated acute pain can lead to life-long chronic pain but there are still few effective opioid-sparing options. A new review reinforces the persistent safety issues.

A family medicine physician shares a case of massive PE presenting as syncope and explains the history questions that prevent missed DVT diagnoses in primary care.

Primary care physicians enhance early detection and management of vascular diseases, emphasizing patient history, screening, and strong relationships for better outcomes.

Your daily dose of the clinical news you may have missed.

Obesity rates in states where it has leveled at 35% decreased for the first time but report authors warn the progress is limited and at risk due to federal budget cuts.

The Frist Clinic clinician said that technical difficulty is not impeding CGM uptake in primary care. "The real limitation is they just haven't done it before."

A multidisciplinary lung cancer screening program significantly boosts screening rates, ensuring timely follow-ups and early diagnoses for eligible patients.

The Menopause Society 2025 Annual Meeting, Oct 21-25, in Orlando, will focus on optimizing women's health and longevity at menopause and beyond. Highlights here.

Your daily dose of the clinical news you may have missed.

Highlights include size-based surveillance protocols, referral timing, cardiovascular risk reduction, and coordination with vascular surgery.

Merck reveals promising phase 3 results for DOR/ISL, showing minimal impact on weight and lipids in adults with suppressed HIV-1.

A study reveals that starting benzodiazepines or antipsychotics in hospice patients with dementia significantly increases 180-day mortality, urging careful prescribing.